LIPOSOMAL FORMULATION WITH THE NISTATIN DRUG

摘要

liposomal formulation with the drug nystatin the present invention deals with the development of liposomal formulation, containing nystatin intended for applications in systemic mycoses, as well as, reducing the toxicity of the drug when applied in parenteral form. the invention is capable of carrying the antifungal nystatin and promoting a sustained release of said drug. the invention involves the preparation of a liposomal formulation with a composition in molar percentage of: 70% hydrogenated phosphatidylcholine (hspc); 20% cholesterol; 10% of distearoylphosphatidylglycerol (dspg), 1.3% of 2,6 - bis (1,1-dimethyl) - 4 - methyl phenol (bht) and 7% of nystatin, the physicochemical characterization of the system and the investigation of biological activity, by the susceptibility test. the preparations were tested with yeasts of the genera candida and cryptococcus. the liposomal formulation with the drug nystatin applies, especially, to individuals with systemic miscoses, such as: the immunodepressed.